MS: Busting the Myths
December 22, 2017 | Advocacy, Treatments
Media Release – 22 December 2017 The Multiple Sclerosis Society of New Zealand (MSNZ) is pleased that Medsafe[1] has approved the registration of ocrelizumab (Ocrevus®) for both Relapsing (RMS) and Primary Progressive (PPMS) multiple sclerosis (MS) in New Zealand. […]
December 7, 2017 | Research, Treatments, Uncategorised
As part of Multiple Sclerosis NZ’s 50th Anniversary, in October we held a lecture evening on the future of MS treatments. To watch lectures from two prominent speakers in their field, click on the lecture titles below: Stem Cell Transplantation […]
November 9, 2017 | Advocacy, Life with MS, Research, Treatments
Following TVNZs Sunday programme last night on people with multiple sclerosis seeking stem cell transplantation overseas for their MS, the Multiple Sclerosis Society of New Zealand (MSNZ) confirms its support for the use of this treatment within a clinical trial […]
September 18, 2017 | Advocacy, Education, Event, Treatments, Uncategorised
Multiple sclerosis is a chronic neurological condition of the central nervous system affecting 4000 New Zealanders and with 134 new people being diagnosed each year. While the exact cause and cure of MS is currently unknown, there are treatments available, […]
August 22, 2017 | Advocacy, Research, Treatments
Since the FDA in America approved Ocrevus (Ocrelizumab) in March 2017 as a treatment for RRMS and PPMS there has been a lot of interest in seeing this be made available in NZ. MSNZ has reviewed the positive research, been in discussions […]